拉帕替尼在乳腺癌中的应用及其耐药机制研究现状

doi:10.11904/j.issn.1002-3070.2015.04.020

Abstract

Abstract: With development of molecular biology,breast cancer has entered an era of molecular classification,thus making biomarker based personalized medicine is the trend of breast cancer treatment.HER2-positive breast cancer of high invasiveness and bad prognosis accounts for 20%~30%.Targeting HER2,trastuzumab is the first humanized monoclonal antibody which can improve the prognosis of HER2-positive patients and it is recommended by guidelines and expert consensus at home and abroad for anti-HER2 therapy in any stage.However,the cardiotoxicity,de novo resistance and acquired resistance of trastuzumab make the clinician to explore the second line anti-HER2 therapy.Lapatinib is the first FDA approved and HER1,HER2 double-targeting tyrosine kinase inhibitor which can be a better choice after failure with trastuzumab.This article reviews the application,some clinical and mechanism of drug resistance researches of Lapatinib.

Key words: Breast neoplasms, Receptor, Epidermal growth factor, Lapatinib

CLC Number:

R737.9

DU Ge,JIANG Zefei. The application of Lapatinib in breast cancer and its mechanism of drug resistance[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 376-379.

References

1 Gradishar WJ,Anderson BO,Blair SL,et al.Breast cancer version 3.2014[J].J Natl Compr Canc Netw,2014,12(4):542-590.
2 Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
3 宋金洁,王涛,边莉,等.曲妥珠单抗联合蒽环类药物应用于Her-2阳性乳腺癌的新辅助治疗初步临床研究[J].实用肿瘤学杂志,2013,27(2):97-100.
4 Bian L,Wang T,Zhang S,et al.Trastuzumab plus capecitabine vs.lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer[J].Tumor Biol,2013,34(5):3153-3158.
5 Hynes NE,Lane HA.ERBB receptors and cancer:the complexity of targeted inhibitors[J].Nat Rev Cancer,2005,5(5):341-354.
6 Hegde PS,Rusnak D,Bertiaux M,et al.Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles[J].Mol Cancer Ther,2007,6(5):1629-1640.
7 Rusnak DW,Lackey K,Affleck K,et al.The effects of the novel,reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor,GW2016,on the growth of human normal and tumor-derived cell lines in vitro and in vivo[J].Mol Cancer Ther,2001,1(2):85-94.
8 Bence AK,Anderson EB,Halepota MA,et al.Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016,a dual EGFR-ErbB2 inhibitor,in healthy subjects[J].Invest New Drug,2005,23(1):39-49.
9 Burris HA,Hurwitz HI,Dees EC,et al.Phase I safety,pharmacokinetics,and clinical activity study of lapatinib(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
10 Burstein HJ,Storniolo AM,Franco S,et al.A phase II study of lapatinibmonotherapy in chemotherpy-refractory HER2-positive and HER2-negativeadvancedmetastatic breast cancer[J].Ann Oncol,2008,19(6):1068-1074.
11 Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733-2743.
12 Di Leo A,Gomez HL,Aziz Z,et al.Phase III,double-blind,randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer[J].J Clin Oncol,2008,26(34):5544-5552.
13 Johnston S,Pippen J,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
14 Bachelot T,Romieu G,Campone M,et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer(LANDSCAPE):a single-group phase 2 study[J].Lancet Oncol,2013,14(1):64-71.
15 Goss PE,Smith IE,O′Shaughnessy J,et al.Adjuvant lapatinib for women with early-stage HER2-positive breast cancer:a randomised,controlled,phase 3 trial[J].Lancet Oncol,2013,14(1):88-96.
16 Baselga J,Bradbury I,Eidtmann H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2012,379(9816):633-640.
17 Robidoux A,Tang G,Rastogi P,et al.Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer(NSABP protocol B-41):an open-label,randomized phase 3 trial[J].Lancet Oncol,2013,14(12):1183-1192.
18 Guarneri V,Frassoldati A,Bottini A,et al.Preoperative chemotherapy plus trastuzumab,lapatinib,or both in human epidermal growth factor receptor2-positive operable breast cancer:results of therandomizedphase II CHER-LOB study[J].J Clin Oncol,2012,30(16):1989-1995.
19 Eichhorn PJ,Gili M,Scaltriti M,et al.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235[J].Cancer Res,2008,68(22):9221-9230.
20 Junttila TT,Akita RW,Parsons K,et al.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941[J].Cancer Cell,2009,15(5):429-440.
21 O′Brien NA,Browne BC,Chow L,et al.Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib[J].Mol Cancer Ther,2010,9(6):1489-1502.
22 Zoppoli G,Moran E,Soncini D,et al.Ras-induced resistance to lapatinib is overcome by MEK inhibition[J].Curr Cancer Drug Tar,2010,10(2):168-175.
23 Xia W,Bacus S,Hegde P,et al.A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer[J].P Natl Acad Sci,2006,103(20):7795-7800.
24 Baselga J,Bradbury I,Eidtmann H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2012,379(9816):633-640.
25 McDonagh CF,Huhalov A,Harms BD,et al.Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3[J].Mol Cancerther,2012,11(3):582-593.
26 Liu L,Greger J,Shi H,et al.Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells:activation of AXL[J].Cancer Res,2009,69(17):6871-6878.
27 周金妹,江泽飞.液体肿瘤生物指标检测对乳腺癌患者的价值[J].中国癌症杂志,2014,24(8):636-640.

[1]	LIU Hengchen, ZHANG Xinyu. Toll-like receptor signaling pathway as a potential therapeutic target for colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 188-192.
[2]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.
[3]	JIANG Tao,ZHANG Xu. The research progress of orphan nuclear receptors in prostate cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 377-380.
[4]	YAN Shi, HUO Mingming, PANG Hui, LI Yan, CAI Li. Effects of p53 on predictive value for efficacy of endocrine drugs in postoperative postmenopausal breast cancer patients with HR positive and HER-2 positive [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 234-213.
[5]	WANG Xiaoxiao, HUA Teng, WANG Hongbo. Research progress of estrogen receptor-related receptor γ in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 87-91.
[6]	WANG Shuo, SONG Yanni. Advances in pathogenesis of breast Paget's disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 444-447.
[7]	TANG Xiaosong,CHEN Gongyan. Research progress of receptor tyrosine kinase AXL in tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 281-284.
[8]	TANG Dabei,JIN Yan,GONG Zhenqin,CHU Zhong,CAO Zhongru,ZHANG Qingyuan. Expression of miR-124 and its relationship with E-cadherin and androgen receptor in triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 97-101.
[9]	YU Fei,HU Jing,CHEN Xuesong. Research progress of tamoxifen resistance mechanism in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 160-164.
[10]	SANG Xiuli, SHI Ce, ZHOU Jin. The research development of Chimeric Antigen Receptor T-cells in hematological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 473-476.
[11]	WANG Ting,CHEN Xuesong. Research progresses of Renin-angiotensin system receptors in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 365-369.
[12]	WANG Lin,MENG Xiangning. Research progress on targeted drugs of human epidermal growth factor receptor 2 positive tumours [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 266-270.
[13]	LIU Wei,LI Huiyan. Progress in relationship between epidermal growth factor receptor and radiosensitivity [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 275-278.
[14]	ZHANG Rui, WANG Zhiyu, WEN Xiaoting, ZHAO Hui. Study progresses of tumor immunosuppressive microenvironment in tumor immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 167-171.
[15]	CUI Jialin, HUANG Rui, JIANG Yongdong, HAN Jiguang, NIU Ming, WEI Wei, ZHENG Wei, SONG Yanni. Related research of male breast cancer and CAG repeat polymorphism of AR gene [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 492-496.

The application of Lapatinib in breast cancer and its mechanism of drug resistance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments